Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer

Nuri Arslan; Tom R. Miller; Farrokh Dehdashti; Richard J. Battafarano; Barry A. Siegel

doi:10.1016/S1536-1632(02)00011-2

Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[¹⁸F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer

Nuri Arslan, Tom R. Miller, Farrokh Dehdashti, Richard J. Battafarano, Barry A. Siegel

Research output: Contribution to journal › Article › peer-review

70 Scopus citations

Abstract

Purpose: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[¹⁸F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. Procedures: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV _peak), average SUV (SUV_ave), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. Results: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. Conclusions: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.

Original language	English (US)
Pages (from-to)	301-310
Number of pages	10
Journal	Molecular Imaging and Biology
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/S1536-1632(02)00011-2
State	Published - Jan 1 2002
Externally published	Yes

Keywords

Esophageal cancer
FDG-PET
Response evaluation

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/S1536-1632(02)00011-2

Cite this

@article{38ddedf771f740e9b8d38d7a28be80d0,

title = "Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer",

abstract = "Purpose: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. Procedures: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV peak), average SUV (SUVave), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. Results: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. Conclusions: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.",

keywords = "Esophageal cancer, FDG-PET, Response evaluation",

author = "Nuri Arslan and Miller, {Tom R.} and Farrokh Dehdashti and Battafarano, {Richard J.} and Siegel, {Barry A.}",

year = "2002",

month = jan,

day = "1",

doi = "10.1016/S1536-1632(02)00011-2",

language = "English (US)",

volume = "4",

pages = "301--310",

journal = "Molecular Imaging and Biology",

issn = "1536-1632",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer

AU - Arslan, Nuri

AU - Miller, Tom R.

AU - Dehdashti, Farrokh

AU - Battafarano, Richard J.

AU - Siegel, Barry A.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Purpose: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. Procedures: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV peak), average SUV (SUVave), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. Results: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. Conclusions: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.

AB - Purpose: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. Procedures: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV peak), average SUV (SUVave), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. Results: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. Conclusions: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.

KW - Esophageal cancer

KW - FDG-PET

KW - Response evaluation

UR - http://www.scopus.com/inward/record.url?scp=0036660972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036660972&partnerID=8YFLogxK

U2 - 10.1016/S1536-1632(02)00011-2

DO - 10.1016/S1536-1632(02)00011-2

M3 - Article

C2 - 14537121

AN - SCOPUS:0036660972

SN - 1536-1632

VL - 4

SP - 301

EP - 310

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

IS - 4

ER -